Incepta Pharmaceuticals and Niagen Bioscience outperformed market gains this year, with investors using Zacks Rank to track earnings revisions.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Incepta Pharmaceuticals and Niagen Bioscience outperformed market gains this year, with investors using Zacks Rank to track earnings revisions.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- ZacksNiagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per sha